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Sphingolipids  are  essential  components  of  eukaryotic  cell membranes,  particularly  the  plasma  mem-
brane,  and  are  involved  in  a  diverse  array  of signal  transduction  pathways.  Mammals  produce
sphingomyelin  (SM)  as  the  primary  complex  sphingolipid  via  the  well  characterised  SM synthase.  In  con-
trast yeast,  plants  and  some  protozoa  utilise  an  evolutionarily  related  inositol  phosphorylceramide  (IPC)
synthase to  synthesise  IPC.  This  activity  has  no  mammalian  equivalent  and IPC  synthase  has  been  pro-
posed  as  a target  for  anti-fungals  and  anti-protozoals.  However,  detailed  knowledge  of  the sphingolipid
biosynthetic  pathway  of  the apicomplexan  protozoan  parasites  was  lacking.  In this  study  bioinformatic
analyses  indicated  a  single  copy  orthologue  of the  putative  SM synthase  from  the apicomplexan  Plas-
modium  falciparum  (the  causative  agent  of  malaria)  was  a  bona  ﬁde  sphingolipid  synthase  in the  related
model  parasite,  Toxoplasma  gondii  (TgSLS).  Subsequently,  TgSLS  was  indicated,  by  complementation  of  a
mutant  cell  line,  to be  a functional  orthologue  of  the  yeast  IPC  synthase  (AUR1p),  demonstrating  resis-
tance  to the  well  characterised  AUR1p  inhibitor  aureobasidin  A. In vitro,  recombinant  TgSLS  exhibited
IPC  synthase  activity  and,  for the  ﬁrst  time,  the  presence  of IPC  was  demonstrated  in  T. gondii  lipid
extracts  by  mass  spectrometry.  Furthermore,  host  sphingolipid  biosynthesis  was  indicated  to  inﬂuence,
but  be non-essential  for,  T. gondii  proliferation,  suggesting  that  whilst  scavenging  does  take  place  de novo
ay  besphingolipid  synthesis  m
. IntroductionToxoplasma gondii is an obligate, intracellular protozoan para-
ite, which is able to invade and colonise a wide variety of nucleated
Abbreviations: PI, phosphatidylinositol; PC, phosphatidylcholine; PE, phos-
hatidylethanolamine; IPC, inositol phosphorylceramide; SM,  sphingomyelin;
PE, ceramide phosphorylethanolamine; NBD, C6-ceramide-N-[6-[(7-nitro-
-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-d-erythro-sphingosine; CHAPS,
-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate; TgSLS, Toxo-
lasma gondii sphingolipid synthase; MEF, mouse embryonic ﬁbroblasts.
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vertebrate cells. It is a member of the Apicomplexa, a diverse
phylum including important pathogens of humans and domes-
tic animals such as Plasmodium (the causative agent of malaria),
Cryptosporidium (diarrhoea), Eimeria (coccidiosis in poultry) and
Theileria (East Coast Fever in cattle). Toxoplasma has emerged as
an opportunistic pathogen and toxoplasmosis is an important dis-
ease in the immunocompromised, particularly AIDS patients, those
receiving anti-cancer chemotherapy and organ transplant recipi-
ents [1]. Toxoplasma infection in utero is also a signiﬁcant cause
of congenital defects in humans [1] and spontaneous abortion in
economically important domestic animals [2].
Sphingolipids are amphipathic lipids comprising sphingosine
Open access under CC BY license.as the basic building unit. More complex sphingolipids consist of
a sphingosine backbone N-acylated with a long-chain fatty acid
(i.e. ceramide) and substituted with a head group moiety (e.g.
sphingomyelin, glucosylceramide and ceramide-1-phosphate) [3].
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eramide is a sphingolipid that functions as a secondary messen-
er in ubiquitous, evolutionarily conserved, signalling mechanisms
4]. Complex sphingolipids are major components of the outer
eaﬂet of eukaryotic plasma membranes that are thought to be
nvolved, together with sterols, in the formation of micro-domains
nown as lipid rafts. These rafts have been proposed to func-
ion in a diverse array of processes from the polarised trafﬁcking
f lipid-modiﬁed proteins, to the assembly and activation of sig-
al transduction complexes [5].  In the apicomplexan Plasmodium
pecies, sphingolipid-enriched lipid rafts have been implicated in
he interaction of the parasite with the host erythrocyte through the
rafﬁcking of both host and parasite glycosylphosphatidylinositol
GPI) anchored proteins [6].  In addition, it has been demonstrated,
y the incorporation of tritiated serine, that both Plasmodium
alciparum and T. gondii synthesise sphingolipids de novo [7,8].
ike mammals, P. falciparum synthesises the complex phospho-
phingolipid sphingomyelin (SM) [9–11] and an orthologue of
he mammalian enzyme, SM synthase, has been identiﬁed from
he genome database [12]. T. gondii has also been indicated to
ynthesise SM,  although at relatively low levels compared to
lycosphingolipids [8],  and the presence of this species has subse-
uently been conﬁrmed using mass spectrometry [13]. However,
he enzyme responsible for any SM synthase activity has remained
nidentiﬁed in T. gondii,  and uncharacterised in any apicomplexan.
urthermore, it has also been reported that the parasites harbour
elatively high quantities of ceramide phosphorylethanolamine
CPE), a non-abundant species in mammalian cells [13]. In addition,
he synthesis of the non-mammalian phosphosphingolipid, inosi-
ol phosphorylceramide (IPC), has also been reported in T. gondii
14]. Importantly, the biosynthetic enzyme, IPC synthase, has been
alidated as a drug target in both the fungi and the kinetoplastid
rotozoa [15–18],  and its inhibition by the anti-fungal aureobasidin
 has been proposed in T. gondii [14].
Notably, in addition to de novo synthesis, intracellular parasites
uch as T. gondii may  scavenge sphingolipids or their precursors
rom the host cell [19]. Indeed it has been suggested that the CPE
and SM)  found in intracellular tachyzoites forms may  result from
he concentration of non-abundant host-derived lipid [13]. Within
he host cell T. gondii resides within a specialised parasitophorous
acuole (PV) formed immediately after invasion and delineated
y the PV membrane (PVM) [20]. Although the PV resists fusion
ith host organelles it does demonstrate an intimate, high afﬁnity
ssociation with the ER and mitochondrion [21], the latter facili-
ating the scavenging of host lipoic acid [22]. Furthermore, recent
ork has indicated that host-derived lipid is the primary contrib-
tor to the intravacuolar network that ﬁlls the lumen of the PV
23]. Toxoplasma scavenges a variety of fatty acids and lipids from
he host, including phospholipids and cholesterol, some of which
re further metabolised by the parasite [24,25].  The mechanism
f lipid scavenging is unclear, although current data argue against
assive diffusion, acquisition on invasion [25] and (at least in the
ase of cholesterol) vesicular trafﬁcking [24]. It has been proposed
hat the transport of cholesterol to the PV could be mediated via
 protein carrier [24], and the possibility of direct inter-organelle
ransfer of lipids between the closely associated PVM and host ER
nd mitochondrial membranes has been evoked [22,25]. The bal-
nce between de novo synthesised and scavenged lipid is unclear,
owever when host phosphatidylcholine (PC) levels are restricted
t is likely that the parasites scavenge choline and synthesise PC de
ovo [25].
To begin to understand the role of both de novo synthesis and
cavenging of sphingolipid for T. gondii,  we aimed to begin char-
cterisation of the little understood parasite biosynthetic pathway
nd investigate the requirement, if any, for host sphingolipid. To
hese ends we herein report the identiﬁcation and functional char-
cterisation of a key enzyme in T. gondii sphingolipid synthesisl Parasitology 187 (2013) 43– 51
that may  represent a novel drug target and, in addition, show the
delineation of the role of host biosynthesis in parasite proliferation.
2. Materials and methods
2.1. Selection, sequence analyses and cloning of candidate
sphingolipid synthase
The T. gondii genome database (www.toxodb.org) was inter-
rogated (Gish, 1996–2001) (http://blast.wustl.edu) with the two
candidate sphingolipid synthase coding sequences previously
identiﬁed from the genome database of the malaria parasite P. fal-
ciparum (plasmodb.org) [12]. A single sequence orthologue was
identiﬁed, TgSLS accession number TGME49 046490, correspond-
ing to the entry previously identiﬁed [13]. Sequence alignments
were made using ClustalW [26] and phylogenetic analyses per-
formed on the edited alignments using Maximum Parsimony,
Protein Distance (PHYLIP Phylogeny Inference Package, version
3.5c) and Maximum Likelihood [27]. The candidate TgSLS open
reading frame was  ampliﬁed from genomic T. gondii DNA using
Pfu polymerase (Promega) and the primer pair 5′TgSLSEcoRI (cgc-
gaattcATGCCCAGAACAGAGATG) and 3′TgSLS*HindIII (cccaagcttT-
TAGAGTCCCTCGATGGCGCGAACGAT). Cloning sites shown in lower
case, with coding sequence in upper case. The product was puriﬁed,
digested and cloned into the yeast expression vector pRS426MET25
creating pRS426 TgSLS.
2.2. Functional complementation of auxotrophic yeast AUR1
mutant
pRS426 TgSLS, together with pRS426 AUR1 and empty vector,
were used to transform the YPH499-HIS-GAL-AUR1 Saccharomyces
cerevisiae strain [28]. Transformants were selected on non-
permissive SD-HIS-URA medium (0.17% Bacto yeast nitrogen base,
0.5% ammonium sulphate and 2% dextrose) or permissive SGR-HIS-
URA medium (0.17% Bacto yeast nitrogen base, 0.5% ammonium
sulphate, 4% galactose and 2% rafﬁnose) containing the appropriate
nutritional supplements at 30 ◦C.
2.3. In vitro assay of TgSLS activity
Microsomal membranes from exponentially growing YPH499-
HIS-GAL-AUR1 pRS426 TgSLS or pRS426 AUR1 in SD-HIS-URA
were prepared and the isolated membrane fraction re-suspended
in storage buffer (50 mM Tris–HCl pH 7.4, 20% (v/v) glycerol,
5 mM MgCl2) with Complete® EDTA-free Protease Inhibitor Cock-
tail (Roche Applied Science) at a protein concentration of 10 mg/ml
as described previously [18]. Microsomal membranes were sub-
sequently washed in 40 mM CHAPS (4 ◦C, 60 min), isolated by
centrifugation (150,000 × g, 4 ◦C and 100 min), re-suspended in
storage buffer at 10 mg/ml  and stored at −80 ◦C until use. The
assay mix  contained 1 mM donor substrate (bovine liver PI, PC or
PE, Avanti Polar Lipids), 20 g microsome prep, 100 mM Tris–HCl,
10 mM EDTA, 6 mg/ml  BSA and 5 M NBD C6-ceramide [19]. Fol-
lowing incubation at 30 ◦C for 60 min  the reaction was quenched by
the addition of 150 l of chloroform:methanol:water (10:10:3) and
lipids separated and analysed as above. For inhibition experiments
the reaction mix  was pre-incubated for 30 min  with appropriate
quantities of aureobasidin A (Takara Bio Inc.) before the addition of
NBD C6-ceramide.
2.4. Agar diffusion assayYPH499-HIS-GAL-AUR1 complemented with TgSLS or AUR1
were assayed for susceptibility to aureobasidin A and myriocin
(Sigma) as previously described [28]. Brieﬂy, 2.4 OD600 units of
S. Pratt et al. / Molecular & Biochemical Parasitology 187 (2013) 43– 51 45
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cig. 1. Identiﬁcation of a candidate sphingolipid synthase from Toxoplasma gondii (T
 and TgSLS. The positions highlighted in black are fully conserved; those in dark g
f  weakly similar groups. The 3 residues of the predicted catalytic triad within D3 a
ogarithmically dividing cells were embedded in 15 ml  of SD-HIS-
RA with 0.8% agarose on 100 mm2 square Petri dishes (Sarstedt).
nhibitors were applied in DMSO at the concentrations indicated
nd the dishes incubated at 30 ◦C.
.5. Mass spectrometry of T. gondii inositol phosphorylceramide
T. gondii (strain RH) were harvested from infected MEF  host
ells by passage through a 26 gauge needle and puriﬁed by sep-
ration on Sephadex-G25 columns (Amersham). Following PBS
ash, the parasites were transferred to glass vials. Sphingolipid
xtracts were prepared as described [29] and analysed. The liquid
hromatography-mass spectrometer consisted of a Waters Aquity
PLC system connected to a Waters LCT Premier orthogonal accel-
rated time of ﬂight mass spectrometer (Waters, Millford, MA),
perated in negative electrospray ionisation mode. Mass accu-
acy and reproducibility were maintained by using an independent
eference spray by the LockSpray interference. The analytical col-
mn  was a 100 mm × 2.1 mm i.d., 1.7 mm C8 Acquity UPLC BEH
Waters). The two mobile phases were A: methanol:water:formic
cid (74:25:1); B: methanol:formic acid (99:1), both also contained
 mM ammonium formate. A linear gradient was programmed as
ollows: 0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 15 min: 99% B;
ig. 2. TgSLS complements a yeast AUR1p auxotrophic mutant. The growth of YPH499 H
nd  a negative control (empty pRS426, pRS) was  supported on permissive SGR media (ga
ould  grow on non-permissive SD media (glucose as carbon source).. Protein sequence alignment of D1, D2, D3 and D4 from HsSMS1 and 2, PfSMS1 and
ow conservation of strongly similar groups; those in light grey show conservation
 are designated by *.
18 min: 99% B; 20 min: 80% B. The ﬂow rate was 0.3 ml/min. Positive
identiﬁcation of all sphingolipid species was based on the accurate
mass measurement with an error <5 ppm and their LC retention
time.
2.6. Cell culture
T. gondii (strain RH, TATi-1; a kind gift from Prof Dominique
Soldati-Favre, University of Geneva) were maintained in Vero cells
grown in DMEM supplemented with 10% foetal bovine serum
(FBS) at 37 ◦C and 5% CO2. Parasites were separated from host cell
material by ﬁltration through 3 and 5 m polycarbonate ﬁlters
(Millipore) after disruption by passage through a 26 gauge needle.
Chinese Hamster Ovary (CHO-K1) cells, the derived temperature
sensitive serine palmitoyl transferase mutant SPB-1, plus SPB-1
complemented with cLCB-1 [30] were grown in Ham’s F-12 media
(Sigma–Aldrich) supplemented with 10% FBS (Gibco) at 37 ◦C or
33 ◦C (SPB-1 permissive temperature) with 5% CO2.2.7. Suppression of host sphingolipid synthesis
For induction of the temperature-sensitive phenotype 105 cells
were seeded into 24-well plates and incubated at 33 ◦C for 24 h.
IS-GAL-AUR1 transformed with pRS426 TgSLS, a positive control (pRS426 ScAUR1)
lactose as carbon source). In contrast, only pRS426 TgSLS and the positive control
46 S. Pratt et al. / Molecular & Biochemica
Fig. 3. TgSLS functions as an inositol phosphorylceramide synthase. HPTLC fraction-
ation of lipids after reaction of CHAPS-washed TgSLS extract with acceptor substrate
NBD-C6-ceramide and either no donor substrate (−) or phosphatidylinositol (PI),
phosphatidylethanolamine (PE) or phosphatidylcholine (PC). Only the addition of PI
led to a signiﬁcant increase in the product formation, a species migrating with ino-
sitol  phosphorylceramide (IPC). A representative image, O was the origin, ceramide
(Cer) migrated at the front, markers from extracts of NBD-C6-ceramide labelled yeast
(
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Given the evidence that Toxoplasma synthesise SM [7], IPCNBD-IPC) and mammalian Vero cells (NBD-SM).
he medium was  then replaced with Ham’s F12 medium supple-
ented with 10% FBS or, to form serum reduced media, 0.1% FBS, 1%
utridoma-SP (Roche Applied Science), 250 M oleic acid (Sigma
ldrich) and 5% fatty acid free Bovine Serum Albumen (BSA; Sigma
ldrich). The low-serum medium contains less than 1 M sphin-
omyelin [31]. As indicated, myriocin (Sigma Aldrich) was  added
t this stage. Cells were then incubated at 39 ◦C for 72 h before T.
ondii,  puriﬁed as above, were added at a ratio of 2 parasites to 1
ost cell and allowed to invade for 4 h. Subsequently, after wash-
ng with PBS, cells were incubated for a further 24 h in normal
r serum reduced media before assay. Cell viability under these
onditions was conﬁrmed by staining with trypan blue (Sigma
ldrich).
.8. Parasite invasion
T. gondii infected cells were ﬁxed with methanol at −20 ◦C for
0 min, dried and stained with 300 nM DAPI in PBS for 5 min. Visual-
sation using an Olympus 1X-71 epiﬂuorescent microscope allowed
nvasion to be scored.l Parasitology 187 (2013) 43– 51
2.9. Parasite proliferation
Following the 4 h invasion time, 1.0 Ci of [5,6-3H] uracil (GE
Healthcare) was added per well and cultures incubated for 24 h.
Supernatant was removed and cells then solublised with 250 l of
1% (w/v) SDS containing 400 g of unlabelled uracil/ml. 750 l of
0.3 M TCA was then added and, after a 15 min incubation at 4 ◦C,
precipitates were collected onto glass ﬁbre ﬁlters in 96 well plates
(Multiscreen HTS, Millipore) using a sampling manifold. The ﬁlters
were washed twice with 0.3 M TCA and once with 95% ethanol,
dried, placed in 10 ml  of scintillation cocktail and the incorporated
radioactivity then measured (Wallac 1450 MicroBeta TriLux, Perkin
Elmer).
3. Results and discussion
3.1. Identiﬁcation of the T. gondii sphingolipid synthase
Although T. gondii has been demonstrated to synthesise com-
plex sphingolipids de novo [7,8], the identity of the enzymes
responsible for this have remained unclear. However, it has
been shown, by incorporation of tritiated inositol, that T. gondii
tachyzoites synthesise the non-mammalian, complex phosphos-
phingolipid, inositol phosphorylceramide (IPC) [14]. In addition,
the synthesis of glycosphingolipids and sphingomyelin (SM), the
predominant mammalian phosphospingolipid, have been similarly
demonstrated [7,8]. Previous bioinformatic analyses have identi-
ﬁed 2 orthologues of the mammalian SM synthase encoded by P.
falciparum, PfSMS1 and 2 [12], an apicomplexan known to synthe-
sise this sphingolipid species [9],  and a single putative orthologue in
the T. gondii genome [13]. This T. gondii predicted protein demon-
strated only 28% and 27% identity to PfSMS1 and 2 respectively.
However, further analyses of the predicted amino acid sequence
identiﬁed the canonical SM synthase domains (D1-4) [12] (Fig. 1),
strongly suggesting that this predicted protein is evolutionarily and
functionally related to this class of enzymes. Phylogenetic analyses
using the Maximum Parsimony algorithm (PHYLIP Phylogeny Infer-
ence Package, version 3.5c), of aligned amino acid sequence (TgSLS
amino acids 92–362) including the active site residues deﬁned by
D3 and D4, supported this hypothesis and indicated that the api-
complexan sphingolipid (SL) synthases form a new group in a wider
enzyme family that includes both SM and IPC synthases (Figure
S1) [32]. However, further analyses using Maximum Likelihood
and Protein Distance (PHYLIP) algorithms (data not shown) failed
to support this result demonstrating the surprising divergence of
TgSLS with respect to the other sphingolipid synthases, including
PfSMS1 and 2.
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.molbiopara.
2012.11.007.
No functional analyses of these apicomplexan enzymes has pre-
viously been undertaken. Therefore, the open reading frame of the
putative Toxoplasma SL synthase (TgSLS) was  cloned into an URA3
selectable expression vector creating pRS426 TgSLS. Ectopic expres-
sion from this vector was subsequently demonstrated to restore
the grow of YPH499-HIS-GAL-AUR1, the previously constructed
AUR1 auxotrophic mutant [27], in non-permissive glucose contain-
ing media (Fig. 2). These data indicated that TgSLS is a functional
orthologue of the yeast IPC synthase, AUR1p [33].
3.2. The functionality of the T. gondii sphingolipid synthase[14] and, perhaps, CPE [13] it was necessary to ascertain the
functionality of TgSLS. To this end, microsomes were prepared
S. Pratt et al. / Molecular & Biochemical Parasitology 187 (2013) 43– 51 47
Fig. 4. Inositol phosphorylceramide identiﬁcation in Toxoplasma gondii lipid extracts. (A) Selected negative ion m/z 778.5234 (inositol phosphorylceramide, N-hexadecanoyl
(N-C16) species, IPC); (B) selected negative ion m/z  747.5652 (sphingomyelin, N-hexadecanoyl (N-C16) species, SM); and (C) selected negative ion m/z 659.5128 (ceramide
phosphorylethanolamine, N-hexadecanoyl (N-C16) species, CPE) UPLC–TOF chromatograms of mouse embryonic ﬁbroblast (MEF) host cells and T. gondii lipid extracts. (D)
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PC  and (M + HCOO−) for SM.  CPE and SM were found in both samples, whereas IPC
rom YPH499-HIS-GAL-AUR1 pRS426 TgSLS and formatted into an
n vitro assay as previously described for other enzymes of this class
17,18,32]. The detergent wash in the preparation of the micro-
omes in this process removes lipids and therefore renders the
nzyme largely dependent on the addition of exogenous substrate,
he labelled acceptor substrate NBD-C6-ceramide and the donor
ubstrate, phosphatidylinositol (for IPC synthesis) or phosphatidyl-
holine (for SM)  [17]. TgSLS clearly synthesises a product migrating
ith IPC on the addition of exogenous PI, but no evidence for the
tilisation of PC for SM synthesis or phosphatidylethanolamine (PE)
or CPE synthesis was seen under the conditions employed (Fig. 3).
he Toxoplasma enzyme clearly functions as an IPC synthase, an
ctivity that is increased approximately 5-fold on the addition of
he donor substrate PI to the assay (Figure S2A). There was also
 small increase in IPC signal on the addition of both PC and PE.
his small effect was consistent across four repeats and could be
ue to these lipids altering the composition of the micelles formed
fter the CHAPS wash, perhaps leading to increased availability of
he remaining endogenous PI. In contrast, the yeast IPC synthase,
UR1p, is non-responsive to the mammalian PI employed in this
ssay system (Figure S2B) [18].
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.molbiopara.2012.11.007.
.3. Inositol phosphorylceramide in T. gondii
Lipidomic analyses have identiﬁed the presence of SM,  CPE,
ut not IPC in Toxoplasma [13]. Therefore, in order to investigate
hether the parasite harbours this non-mammalian sphingolipid
pecies analyses by liquid chromatography–mass spectrometry
LC–MS) [34] of lipids extracted from isolated T. gondii and hostpresentative chromatogram obtained by UPLC/TOF-ESI(−) analysis of lipid extracts
ss spectral pattern for the molecular ion region showing an (M–H)-ion for CPE and
nly identiﬁed in T. gondii extracts.
mouse embryonic ﬁbroblast (MEF) cells were performed (Fig. 4).
The unambiguous identiﬁcation of IPC was achieved by accurate
mass determination by high resolution time-of-ﬂight (TOF) mass
spectrometry. A selected negative ion UPLC–TOF chromatogram,
corresponding to the deprotonated C16-IPC species, of the T. gondii
lipid extract exhibited a peak absent in the mammalian host
cells (Fig. 4A). In contrast, selected negative ions corresponding
to the formic acid adduct of SM (Fig. 4B) and deprotonated CPE
(Fig. 4C) were detected in both host and parasite extracts, with CPE
appearing enriched in T. gondii as previously recorded [13]. The
mass spectrum of these peaks (Fig. 4D) showed an accurate mass
measurement with errors with respect to the theoretical spectra
(Fig. 4E), of 0.3 ppm and 3.5 ppm for SM and CPE, and 0.6 ppm for
IPC. In addition, they demonstrated very similar isotopic patterns.
These data demonstrate, for the ﬁrst time, the presence of non-
mammalian IPC (C18:1/C16:0) in T. gondii and strongly suggest that
the IPC synthase activity of TgSLS seen in vitro above is also evident
in vivo.
3.4. Inositol phosphorylceramide synthase as a drug target in T.
gondii
The, then uncharacterised, Toxoplasma IPC synthase activity has
previously been proposed as a drug target based on the efﬁcacy of
the potent, well-characterised fungal IPC synthase inhibitor aure-
obasidin A (AbA) against T. gondii within infected host cells [14]. To
test this hypothesis we chose to analyse the sensitivity of YPH499-
HIS-GAL-AUR1 pRS426 TgSLS to AbA by diffusion assay (Fig. 5A).
AbA sensitive YPH499-HIS-GAL-AUR1 pRS426 AUR1 was used as a
positive control and the sphingolipid bypass mutant AGD as a nega-
tive control. AGD is able to grow without synthesising sphingolipids
and therefore is able to tolerate loss-of-function mutations in both
48 S. Pratt et al. / Molecular & Biochemical Parasitology 187 (2013) 43– 51
Fig. 5. TgSLS sensitivity to a veriﬁed yeast AUR1p inhibitor. (A) Agar diffusion assay of YPH499 HIS-GAL-AUR1 complemented yeast showed that, as expected, ScAUR1
complemented yeast were sensitive to myriocin at 1 mM (Myr) and aureobasidin A at 25 M (AbA25). In contrast, TgSLS complemented yeast were resistant to AbA at 25 M
and  100 M (AbA100), but hyper-sensitive to myriocin (1 mM)  as evidenced by large zones of exclusion. AGD, the sphingolipid bypass mutant yeast lacking functional SPT
and  AUR1, acted as the negative control. DMSO was the vehicle control. (B) In vitro assay of the inhibitory effect of aureobasidin A (AbA) on TgSLS demonstrated that the
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aoxoplasma enzyme is only marginally, but signiﬁcantly (p < 0.01), sensitive to the
ollowing fractionation by HPTLC and normalised with respect to an untreated cont
erine palmitoyltransferase and IPC synthase [33]. These results
emonstrated that TgSLS (the Toxoplasma IPC synthase) conferred
bA resistance to the yeast. The hyper-sensitivity to myriocin (an
nhibitor of an upstream step in sphingolipid biosynthesis medi-
ted by serine palmitoyltransferase) resembled that seen in the
ame mutant yeast complemented by the Leishmania major IPC syn-
hase [28]. The reasons for this are unknown but perhaps reﬂect
 sub-optimum functionality of the protozoan sphingolipid syn-
hases in the yeast making the complemented lines more sensitive
o upstream inhibition of sphingolipid biosynthesis.
To further investigate any inhibition of Toxoplasma IPC syn-
hase activity by AbA the microsomal assay described above was
mployed (Fig. 5B). Small, but statistically signiﬁcant, inhibition
f enzyme turnover was noted at 100 M.  However, in contrast it
hould be noted that the aureobasidin A is a tight binding inhibitor
f the yeast IPC synthase (AUR1p) with a reported IC50 of 0.2 nM
33]. Together, these data demonstrate that TgSLS is largely resis-
ant to AbA and, as such, resembles the characterised, AbA-resistant
PC synthase from the kinetoplastid protozoan parasite, L. major
28].
Therefore, TgSLS is not the target for aureobasidin A in T. gondii
nd the previously reported efﬁcacy [14] may  be due to unidentiﬁed at a high concentration (100 M).  Fluorescence intensity of IPC was established
ean of 3 independent experiments, standard deviation indicated.
off target host effects as hypothesised for the kinetoplastid proto-
zoa T. cruzi [35].
3.5. The role of host sphingolipid biosynthesis in T. gondii
proliferation
As demonstrated above and previously [7] T. gondii have the
ability to synthesise sphingolipids de novo. However, as an intra-
cellular parasite T. gondii may  also utilise host sphingolipids. In
order to unravel the roles of host synthesis in parasite proliferation,
Chinese Hamster Ovary (CHO) cells with a temperature sensitive
serine palmitoyltransferase (SPT) were utilised as host cells [30,31].
SPT is the ﬁrst and rate-limiting enzyme in eukaryotic sphingolipid
biosynthesis and in this cell line, SPB-1, the LCB1 subunit of this
heterodimeric enzyme is thermolabile. At the non-permissive tem-
perature virtually no SPT activity is detectable and sphingolipids
are depleted when the SPB-1 cells are grown with minimal sera
[36]. This phenotype is reversed by stable transfection of cDNA
encoding cLCB1 [36]. Like T. gondii,  the bacterial pathogen Chlamy-
dia trachomatis (the causative agent of trachoma) resides within
a non-fusagenic inclusion. Within SPB-1 cells C. trachomatis are
completely unable to replicate at the non-permissive temperature,
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Fig. 6. Analyses of the role of host serine palmitoyltransferase (SPT) in Toxoplasma gondii proliferation and invasion. Cells were cultured in 10% FCS (A) or in serum-reduced
media (B) at the non-permissive temperature (39 ◦C). In the presence of complete media, T. gondii proliferation was  the same in wild type (CHO-K1) and SPT-compromised
(SPB-1)  host cells (A). However, in serum-reduced media proliferation was  signiﬁcantly (p < 0.001) decreased in SPB-1 cells compared to the control (CHO-K1 and SPB-1
cLCB1)  lines (B). All results normalised with respect to proliferation in parental CHO-K1 cells. Analyses of 3 independent experiments performed in triplicate, standard
deviation indicated. This effect was not due to signiﬁcant differential invasion of the host cell lines (p > 0.1; C). Analyses of 3 independent experiments, standard deviation
indicated. To analyse the effect of chemical inhibition of SPT, cells were cultured in serum-reduced media at the non-permissive temperature (39 ◦C) in the presence or
absence  of the inhibitor, myriocin (D). Myriocin treatment reduced Toxoplasma proliferation (p < 0.05) in wild type (CHO-K1) cells to similar levels to those seen in untreated
S  in SP
( tal C
i
d
i
s
m
c
a
p
t
d
i
a
i
c
c
m
c
c
c
i
f
ePT-compromised (SPB-1) host cells. The compound had no effect on proliferation
SPB-cLCB1; p < 0.05). All results normalised with respect to proliferation in paren
ndicated.
emonstrating that host sphingolipid biosynthesis is essential for
ntracellular growth of this pathogen [37] which acquires newly
ynthesised SM via the host exocytic pathway [38–41].
Utilising the same conditions employed in study of C. tracho-
atis replication [37], the proliferation of T. gondii in SPB-1 CHO
ells was investigated. Brieﬂy, before invasion host cells (both SPB-1
nd controls) were incubated for 72 h at the non-permissive tem-
erature (39 ◦C) in either complete or serum-reduced media. In
he same media the cells were infected with isolated T. gondii as
escribed in Section 2, and proliferation established by measur-
ng [3H]-uracil incorporation as previously described [42] (Fig. 6A
nd B). It was clear that under the non-permissive conditions but
n complete media the parasites replicated as well in the SPT deﬁ-
ient SPB-1 cells as they did in the wild type parental line (Fig. 6A). In
ontrast, with serum-reduced media T. gondii proliferation in the ts
utant cells was signiﬁcantly reduced compared with the wild type
ontrol (p < 0.001; Fig. 6B). Notably, this effect was rescued in SPB-1
ells complemented by the expression LCB1 from stably transfected
DNA. Furthermore, these results are not due to differential T. gondii
nvasion as, under these conditions, there was  no signiﬁcant dif-
erence (p > 0.1) in the invasion rate between any of the cell lines
mployed (Fig. 6C). SPT can also be speciﬁcally inhibited by theB-1 cells but exerted a similar effect to wild type in complemented mutant cells
HO-K1 cells. Analyses of experiments performed in triplicate, standard deviation
natural product sphingosine analogue, myriocin [43]. Importantly,
this induced a similar decrease in T. gondii proliferation in wild type
CHO cells to that seen in the SPB-1 mutant. No effect was observed
on treatment of the SPB-1 cells in which SPT activity was already
suppressed, indicating that the effect seen in wild type cells was due
to inhibition of host SPT and not the uncharacterised parasite ortho-
logue (Fig. 6D). This may  be due to the Toxoplasma SPT being either
resistant or inaccessible to myriocin. Alternatively modulation of
parasite SPT activity may  have only a limited effect on prolifera-
tion. However, whilst host sphingolipid biosynthesis clearly plays
a role in parasite replication, unlike for the bacterium C. tracho-
matis [37], it is non-essential. Furthermore, the addition of serum
to the media negated any effect, indicating that scavenging from
the extracellular milieu can compensate for the lack of host SPT
activity. Notably, previous studies of T. gondii development within
enucleated cells did not record any signiﬁcant differences in par-
asite growth compared to nucleated controls [44]. Taken together
these results indicate that host synthesis is not immediately critical
for the ability of the parasite to grow, although prolonged deple-
tion of sphingolipids (both synthesised and exogenous for 96 h)
does inﬂuence proliferation (an approximate 40% reduction). This
contrasts with the intra-cellular kinetoplastid, protozoan parasite
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eishmania mexicana where suppression of host sphingolipid syn-
hesis and depletion of extracellular lipid showed no effect on
arasite proliferation [45].
. Conclusion
T. gondii is an important cause of disease in humans and domes-
ic animals and a model apicomplexan pathogen [46]. The essential,
ukaryotic sphingolipids have been implicated in the interaction of
he related apicomplexan P. falciparum with its anucleate host cell,
he erythrocyte [6].  In this study we utilised the ability of T. gondii
o invade and colonise a wide range of nucleated vertebrate cells
o examine the role host sphingolipid synthesis in invasion and
roliferation. Genetic and chemical inhibition of the host pathway,
oupled with depletion of media lipid, inhibited parasite prolifer-
tion (but not invasion). However, in contrast to the bacterium C.
rachomatis [37], T. gondii was still able to replicate under these
onditions. Notably, while auxotrophic for sterols [24], T. gondii
ave maintained the ability to synthesise sphingolipids de novo [7].
t could be hypothesised that this allows the parasite to survive
nd replicate in conditions of greatly reduced host sphingolipid
iosynthesis. However, the protozoan biosynthetic pathway and
he identity of the enzymes that constitute it remained relatively
ninvestigated. In this study we showed that the identiﬁed T. gondii
L synthase demonstrated IPC synthase activity in vitro, and that
his non-mammalian lipid species is detectable by mass spectrom-
try in parasite extracts. Given the status of the fungal AUR1p and
inetoplastid IPC synthases as promising drug targets [3],  the iden-
iﬁcation of the T. gondii orthologue opens up the possibility of
argeting this enzyme with novel anti-protozoals. However, the
bility of the parasite to scavenge sphingolipid from the host may
omplicate the viability of TgSLS as a pharmaceutical target and
learly the balance between de novo synthesis and scavenging mer-
ts further investigation.
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